| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/10/2013 | WO2013004556A1 A molecule regulating activity of insulin degrading enzyme (ide) |
| 01/10/2013 | WO2013004527A1 A molecule regulating activity of insulin degrading enzyme (ide) |
| 01/10/2013 | WO2013004525A1 A molecule regulating activity of insulin degrading enzyme (ide) |
| 01/10/2013 | WO2013004399A1 Anti - amyloidogenic, alpha-helix breaking ultra-small peptide therapeutics |
| 01/10/2013 | WO2013004249A1 The use of serotonin receptor agonists for treatment of movement disorders |
| 01/10/2013 | WO2013004177A1 Composition of active ingredient of traditional chinese medicine and use thereof |
| 01/10/2013 | WO2013004145A1 Composition of chinese herbal compound or extract and use thereof |
| 01/10/2013 | WO2012158492A3 Treatment and management of cns disorders |
| 01/10/2013 | WO2012138190A3 Composition containing jetbead extracts |
| 01/10/2013 | WO2012117073A3 New compositions for treating neurological disorders |
| 01/10/2013 | WO2012112674A3 Compounds and methods of use thereof for treating neurodegenerative disorders |
| 01/10/2013 | WO2011153819A8 Pharmaceutical composition for treating drug addiction |
| 01/10/2013 | WO2011130834A8 Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof |
| 01/10/2013 | US20130012593 Modified release formulations of memantine oral dosage forms |
| 01/10/2013 | US20130012592 Agomelatine hydrobromide hydrate and preparation thereof |
| 01/10/2013 | US20130012587 Methods of Treating Autism |
| 01/10/2013 | US20130012586 Methods of Treating Fragile X Syndrome |
| 01/10/2013 | US20130012585 Phenylacetic Acid Derivatives |
| 01/10/2013 | US20130012583 Vinyl substituted fatty acids |
| 01/10/2013 | US20130012573 Methods for intracellular delivery of nucleic acids |
| 01/10/2013 | US20130012568 Kits for Detecting Direct Oxidation of Calcium/Calmodulin Dependent Protein Kinase II and Associated Diagnostic and Therapeutic Methods |
| 01/10/2013 | US20130012567 RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/10/2013 | US20130012565 4-hydroxybutyric acid analogs |
| 01/10/2013 | US20130012563 Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
| 01/10/2013 | US20130012559 Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence |
| 01/10/2013 | US20130012549 Method for the Treatment, Alleviation of Symptoms of, Relieving, Improving and Preventing a Cognitive Disease, Disorder or Condition |
| 01/10/2013 | US20130012545 Amido-Thiophene Compounds and Their Use |
| 01/10/2013 | US20130012542 Injectable depot formulation comprising crystals of iloperidone |
| 01/10/2013 | US20130012541 Therapeutic Agents Useful for Treating Pain |
| 01/10/2013 | US20130012536 Modulators of atp-binding cassette transporters |
| 01/10/2013 | US20130012533 Controlled release oxycodone compositions |
| 01/10/2013 | US20130012532 Cyclopropanecarboxylic acid derivative |
| 01/10/2013 | US20130012530 New Positive allosteric modulators of nicotinic acetylcholine receptor |
| 01/10/2013 | US20130012526 Oxazole derivatives useful as modulators of faah |
| 01/10/2013 | US20130012524 Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic |
| 01/10/2013 | US20130012522 New derivatives of propargylamine having neuroprotective capacity for the treatment of alzheimer's and parkinson's diseases |
| 01/10/2013 | US20130012521 Apoptosis signal-regulating kinase inhibitors |
| 01/10/2013 | US20130012520 Trazodone and trazodone hydrochloride in purified form |
| 01/10/2013 | US20130012517 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors |
| 01/10/2013 | US20130012516 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF |
| 01/10/2013 | US20130012515 Fused Bicyclic Pyridine and Pyrazine Derivatives as Kinase Inhibitors |
| 01/10/2013 | US20130012510 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1 and cx3cr1 |
| 01/10/2013 | US20130012509 Novel anxiolytic compounds |
| 01/10/2013 | US20130012508 Novel anxiolytic compounds |
| 01/10/2013 | US20130012507 Substituted pyrrolo-pyrazole derivatives as kinase inhibitors |
| 01/10/2013 | US20130012505 Benzonaphthyridinamines as autotaxin inhibitors |
| 01/10/2013 | US20130012499 Trpv4 antagonists |
| 01/10/2013 | US20130012498 5ht2c receptor modulators |
| 01/10/2013 | US20130012497 Methods for detecting adhd susceptibility and predicting severity and long term outcome of adhd symptoms |
| 01/10/2013 | US20130012495 5ht2c receptor modulators |
| 01/10/2013 | US20130012494 Cyclopropyl-fused-1,3-thiazepines as bace1 and/or bace2 inhibitors |
| 01/10/2013 | US20130012492 Fused heterocyclic compounds as ion channel modulators |
| 01/10/2013 | US20130012491 Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists |
| 01/10/2013 | US20130012485 Organic compounds |
| 01/10/2013 | US20130012483 Novel pharmaceutical composition for the treatment of neurodegenerative or neurovascular diseases |
| 01/10/2013 | US20130012479 Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
| 01/10/2013 | US20130012469 Liquid nucleotides/nucleosides-containing product |
| 01/10/2013 | US20130012464 Glycyrrhizinates of morphinan derivatives |
| 01/10/2013 | US20130012462 Receptor modulators exhibiting neuroprotective and memory enhancing activities |
| 01/10/2013 | US20130012458 7-hydroxy chromones as potent antioxidants |
| 01/10/2013 | US20130012456 Compositions and methods for transport across the blood brain barrier |
| 01/10/2013 | US20130012448 Synthetic peptide amides |
| 01/10/2013 | US20130012447 Protein kinase c-delta inhibitors that protect against cellular injury and inflammation and promote astrocyte proliferation |
| 01/10/2013 | US20130012444 Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
| 01/10/2013 | US20130012443 Methods of treatment of central nervous system hemorrhage using protoporphyrin ix-fe compounds |
| 01/10/2013 | US20130012431 Method For Elevating Prolactin In Mammals |
| 01/10/2013 | US20130012427 Polypeptides |
| 01/10/2013 | US20130011487 Fluorinated block co-polymers |
| 01/10/2013 | US20130011483 Formulations of mazindol |
| 01/10/2013 | US20130011482 Dual component medicament delivery system |
| 01/10/2013 | US20130011479 Double-layer pharmaceutical formulations containing opioid agonists and antagonists |
| 01/10/2013 | US20130011474 Modified and immediate release formulations of memantine |
| 01/10/2013 | US20130011472 Stable pharmaceutical composition and methods of using same |
| 01/10/2013 | US20130011468 Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
| 01/10/2013 | US20130011461 Nicotine-containing chewing gum piece packed in a wrapping of laminate |
| 01/10/2013 | US20130011444 Compositions and methods for overcoming resistance to tramadol |
| 01/10/2013 | US20130011432 Disrupted adenovirus-based vaccine against drugs of abuse |
| 01/10/2013 | US20130011431 Composition Comprising the Amyloid Beta 1-6 Peptide Coupled to a Virus-Like Particle and an Adjuvant |
| 01/10/2013 | US20130011405 Antagonist anti-cd40 monoclonal antibodies and methods for their use |
| 01/10/2013 | US20130011397 Transforming growth factor-beta (TGF-beta) antagonists for use in treating pain |
| 01/10/2013 | US20130011390 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| 01/10/2013 | US20130011371 ESTABLISHMENT OF PATIENT- OR PERSON- SPECIFIC CARDIAC MYOCYTE CELL LINES FROM HUMAN INDUCED PLURIPOTENT STEM CELLS (iPSCs) |
| 01/10/2013 | US20130011343 Chewing gum having sustained release of nicotine |
| 01/10/2013 | US20130011342 Surfactant-free, water-free formable composition and breakable foams and their uses |
| 01/10/2013 | US20130011337 Therapeutic agent and diagnostic agent for mitochondrial dysfunction brain diseases |
| 01/10/2013 | CA2843854A1 Herpes virus vaccine and methods of use |
| 01/10/2013 | CA2841785A1 Compositions and methods for treatment of symptoms in parkinson's disease patients |
| 01/10/2013 | CA2840856A1 Egfr targeted therapy |
| 01/10/2013 | CA2840763A1 Compounds for the treatment of addiction |
| 01/10/2013 | CA2840746A1 Methods of treatment of limited cognitive impairment |
| 01/10/2013 | CA2839350A1 The use of serotonin receptor agonists for treatment of movement disorders |
| 01/10/2013 | CA2837247A1 1 , 2 , 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases |
| 01/09/2013 | EP2543659A1 Dendrimers as non-viral vehicles for gene therapy |
| 01/09/2013 | EP2543385A1 Novel analgesics |
| 01/09/2013 | EP2543383A1 Macrocyclic compounds and methods of treatment |
| 01/09/2013 | EP2543380A1 Neural stem cells proliferation promoting agent |
| 01/09/2013 | EP2542571A1 Oligomer-specific amyloid beta epitope and antibodies |
| 01/09/2013 | EP2542547A2 Compounds, compositions, formulations and their uses in the treatment of diseases related to copper retention or hepatic disorders |
| 01/09/2013 | EP2542539A1 Tetrazole compounds which selectively modulate the cb2 receptor |
| 01/09/2013 | EP2542261A1 Antigen binding proteins specific for serum amyloid p component |